View full meeting coverage »

Eyetube Meeting Coverage:

Retina Updates Spring 2020


Editorially Independent Content, Financially Supported by


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Brolucizumab and Aflibercept in HAWK and HARRIER

  Channels: Retina | Posted 5/13/2020

Rishi P. Singh, MD, explains how particular timepoints in the HAWK and HARRIER trials allow researchers to understand the relationship between detectable disease activity and treatment with aflibercept (Eylea, Regeneron) or brolucizumab (Beovu, Novartis) in patients with wet AMD. Dr. Singh distills information from this post hoc analysis by explaining the practical implications for these study findings.

aflibercept • Clinical Trials • HAWK and HARRIER • retina-meeting-recap • Wet AMD

7 / 10 Series: Retina Updates Spring 2020

These programs are not affiliated with the official program of ARVO 2020.